Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EPS (Basic) readings, the most recent being $0.3 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 150.0% to $0.3 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.98, a 508.33% increase, with the full-year FY2025 number at $0.8, up 233.33% from a year prior.
  • EPS (Basic) hit $0.3 in Q1 2026 for Kiniksa Pharmaceuticals International, up from $0.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.23 in Q3 2022 to a low of -$0.36 in Q1 2022.
  • Median EPS (Basic) over the past 5 years was $0.06 (2022), compared with a mean of $0.2.
  • Biggest five-year swings in EPS (Basic): surged 834.09% in 2022 and later plummeted 133.33% in 2024.
  • Kiniksa Pharmaceuticals International's EPS (Basic) stood at $0.06 in 2022, then soared by 500.0% to $0.36 in 2023, then crashed by 133.33% to -$0.12 in 2024, then soared by 258.33% to $0.19 in 2025, then surged by 57.89% to $0.3 in 2026.
  • The last three reported values for EPS (Basic) were $0.3 (Q1 2026), $0.19 (Q4 2025), and $0.25 (Q3 2025) per Business Quant data.